Duloxetine HCL DR Capsules
Awarded on July 13, 2026. Full description on SAM.gov.
Overview
- Posted
- July 14, 2026
- Notice type
- Award Notice
- NAICS
- 325412: Pharmaceutical Preparation Manufacturing
- Agency
- Department of WarDEFENSE LOGISTICS AGENCY
Notice details
- Office
- TROOP SUPPORT MEDICAL.DLA TROOP SUPPORT
- Place of performance
- Salcete, Goa, 403722
- Last updated
- Oct 28, 2026
- First published
- Last updated on SAM.gov
- Award date
- Jul 13, 2026
- Award amount (SAM.gov award notice)
- $133.2M
Identifiers
- Solicitation number
- SPE2D2-26-D-0008
- Notice ID
- 4f79f301b75d4d79a2fd7299c78acc29
- Award number (PIID)
- SPE2D2-26-D-0008
Description
SPE2D2-26-D-0008 Duloxetine HCL DR Award
Award Overview
Award Number
SPE2D2-26-D-0008
Award Amount (SAM.gov award notice)
$133.2M
Award Date
Jul 13, 2026
Awardee
Awardee UEI
GQLDJJ8AQNN5
Awardee CAGE Code
1HT23
Awardee Address
Camarillo, CA 93012, UNITED STATES
Original Solicitation
Notice ID: 4f79f301b75d4d79a2fd7299c78acc29
Posted Date: Jul 14, 2026
Original Response Deadline: Not specified
More From This Vendor
Top 5 most recent
- $78.72Signed Aug 14, 2026
- $147.36Signed Aug 12, 2026
- $535.44Signed Aug 12, 2026
- $27.3Signed Aug 12, 2026
- $85.96Signed Aug 10, 2026
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
Files (11)
- Download
SPE2D225R0010 0006 updates.pdf
262 KBAdded in Combined Synopsis/Solicitation version 14Posted - Download
SPE2D225R0010 0006 released.pdf
145 KBAdded in Combined Synopsis/Solicitation version 14Posted - Download
SPE2D225R0010 0005 released.PDF
18 KBAdded in Combined Synopsis/Solicitation version 12Posted - Download
SPE2D225R0010 0004 released.pdf
105 KBAdded in Combined Synopsis/Solicitation version 10Posted - Download
SPE2D225R0010 0003 released.pdf
106 KBAdded in Combined Synopsis/Solicitation version 9Posted - Download
Updated Schedule of Supplies P00001.pdf
121 KBAdded in Award Notice version 4Posted - Download
SPE2D225R0010 0002 released.pdf
106 KBAdded in Combined Synopsis/Solicitation version 7Posted - Download
SPE2D226D0008P00001 Bilaterally signed.pdf
86 KBAdded in Award Notice version 4Posted - Download
SPE2D225R0010 0001 released.pdf
107 KBAdded in Combined Synopsis/Solicitation version 7Posted - Download
Duloxetine - SPE2D2-26-D-0008 GSMS signed.pdf
1000 KBAdded in Award Notice version 3Posted - Download
Duloxetine HCL DR SPE2D225R0010 Solicitation release.pdf
1.4 MBAdded in Combined Synopsis/Solicitation version 7Posted
Lifecycle
- 2Version 2Combined Synopsis/SolicitationArchived
Duloxetine HCL DR Capsules
- 3Version 3Award Notice
Type changed from Combined Synopsis/Solicitation to Award Notice
Duloxetine HCL DR Capsules
- 4Version 4Award NoticeCurrent
Duloxetine HCL DR Capsules
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 newly approved drugs will be reviewed: Atebrioz – Skeletal Muscle Relaxants and Combinations – Subclass: NA Emcitate – Thyroid and Antithyroid Agents – Subclass: NA Hibsago – Hepatitis B Agents – Subclass: NA Juvmo – Parkinsons Agents – Subclass: NA Zegfrovy – Lung Cancer – Subclass: EGFR+ NSCLC The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9102. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | - | Solicitation | 11/30/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 drug classes/subclasses will be reviewed: a. Ophthalmic - Dry Eye Cequa Eysuvis Miebo Tryptyr Tyrvaya Verkazia Vevye Xiidra b. Testosterone Replacement Therapy - Orals Jatenzo Kyzatrex Tlando The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9101. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. | - | Solicitation | 12/07/2026 |
The Defense Logistics Agency is issuing a solicitation for a national requirements contract for Epinephrine Injectors. Procurement details follow. Epinephrine 0.3 MG/0.3 ML Injection, Auto-Injector 2S in 2 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov. Interested parties should contact Jeremy Brown at (445) 737-5419, (jeremy.brown@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current solicitation date is October of 2026. | - | Solicitation | 11/30/2026 |
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Fentanyl Citrate Injection Solution. Procurement details follow. Fentanyl (PF) 50 MCG/ML Injection Solution in 1 ML, 2 ML, 5 ML,10 ML, 20 ML and 50 ML in Vials or Ampules, Pack Size of 1, 2, 5, 10, 20, and 50. Competition will be restricted to domestic sources (vendors providing Active Pharmaceutical Ingredients (API) and Final Dosage Forms (FDF) manufactured domestically), the procurement will be competed among all qualified domestic manufacturers. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of War (DoW), Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov/. Interested parties should contact Nancy Fernandez at (445) 737-0731 or Nancy.Fernandedz@dla.mil with any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is November/December of 2026. DLA reserves the right to issue the solicitation before or after the projected solicitation date. | - | Pre-Solicitation | Open |
This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Item 0001: OXYGEN, USP, FILLED CYLINDER, SIZE D, 95GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5181 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0002: OXYGEN, USP, FILLED CYLINDER, SIZE H, 1650 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5199 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0003: NITROUS OXIDE, USP, FILLED CYLINDER, SIZE D, 250 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-130-1920 Shall be made in accordance with MIL-N-37996 DATED 24 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. ----------------------------------------------------- The Defense Logistics Agency Troop Support is seeking sources capable of providing the Medical Gas Cylinder in accordance with the Military Specifications listed above. NOTE: Only Type I-DOT 3AA STEEL Medical Gas Cylinders are acceptable. If your firm currently manufactures or distributes Type I-DOT 3AA STEEL Medical Gas Cylinders in accordance with the Military Specifications and changes attached, please provide information with respect to the following: Source and Part Number being supplied for each type of cylinder Place of manufacture for each type of cylinder Source for the Medical Gases Current unit sale price for each type of cylinder prefilled with the medical grade gas Estimated annual capacity for each type of cylinder/medical grade gas Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the ATNAA. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. Your response to this RFI may be submitted electronically via emailed to Jessica De La Hoz, Contracting Officer, Phone: 445-737-3623, Email: Jessica.DeLaHoz@dla.mil | - | Market Research | 11/15/2026 |
Additional Details
Solicitation Number
SPE2D2-26-D-0008
Archive Date
Jul 12, 2031
Place of Performance Country
INDIA
Office Address
PHILADELPHIA, PA, 19111